Skip to main content
. 2021 Jul 3;77(3):249–257. doi: 10.1016/j.mjafi.2021.06.021

Fig. 8.

Fig. 8

Genetic polymorphism in CYP2C9 inhibits metabolism of warfarin and increases inhibition of VKOR (vitamin K epoxide reductase) which reduces vitamin K which is required for the carboxylation (activation) of coagulation factors VII, IX, and X – bleeding. Genetic polymorphism in VKOR (target for warfarin) prevents reduction of vitamin K – Bleeding. Polymorphisms of both, much higher incidence of bleeding.